Mizuho Securities USA LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 46.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 36,252 shares of the medical research company's stock after acquiring an additional 11,482 shares during the period. Mizuho Securities USA LLC's holdings in Thermo Fisher Scientific were worth $18,859,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Howard Capital Management Group LLC lifted its stake in Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after purchasing an additional 286 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Thermo Fisher Scientific by 22.1% in the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after purchasing an additional 225,568 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Thermo Fisher Scientific by 8.8% in the 3rd quarter. Intech Investment Management LLC now owns 3,417 shares of the medical research company's stock valued at $2,114,000 after acquiring an additional 275 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $235,000. Finally, Integrated Investment Consultants LLC grew its position in Thermo Fisher Scientific by 34.2% in the 3rd quarter. Integrated Investment Consultants LLC now owns 1,009 shares of the medical research company's stock valued at $624,000 after purchasing an additional 257 shares during the period. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Price Performance
NYSE TMO traded down $0.94 on Wednesday, hitting $513.40. 1,216,076 shares of the company were exchanged, compared to its average volume of 1,535,513. The firm has a 50 day moving average of $544.56 and a two-hundred day moving average of $554.22. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market cap of $193.68 billion, a P/E ratio of 31.06, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.34%. Thermo Fisher Scientific's payout ratio is presently 10.41%.
Insider Buying and Selling
In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research report on Friday, January 31st. Raymond James reissued an "outperform" rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Bank of America cut their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Finally, Citigroup lowered their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $653.23.
Get Our Latest Report on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
